InspireMD wins CE Mark for MGuard blood clot stent

March 15, 2013 by Brad Perriello

InspireMD lands CE Mark approval in the European Union for its MGuard embolic protection stent.

InspireMD

InspireMD (OTC:NSPR) said it won a nod from European regulators for its MGuard embolic protection stent, designed to prevent strokes after carotid artery stenting procedures.

The Tel-Aviv-based medical device company said the MGuard device is wrapped with its MicroNet mesh to prevent embolisms – blood clots – from occurring during and after the placement of a carotid stent.

"When treating carotid arterial disease, close to half of carotid artery stenting procedures cause distal embolic events that may lead to stroke within 30 days," according to a press release. "The MicroNet is designed to hold plaque and thrombus in place against the wall of the blocked artery, preventing debris from falling into the bloodstream and causing a potentially fatal downstream blockage or stroke."

Sign up to get our free newsletters delivered straight to your inbox

"The CE Mark approval for our MGuard carotid system is a major milestone for the company and is further validation of  the MicroNet technology. We look forward to accelerating our clinical development program with our carotid system. The CE Mark should enhance our partnership strategy in the near term," president & CEO Alan Milinazzo said in prepared remarks.

 

Comments